- Trial phase
- Phase 3
- Time to market
- If the Phase 3 VALUE trial reads out positive in 2H 2027, an FDA submission could follow in 2027-2028, with potential approval in 2028-2029 at the earliest, assuming no delays.
- Why 5/10
- The next hard, dated catalyst is the interim sample-size reassessment and enrollment completion of the Phase 3 VALUE trial, expected by end of Q1 2027 (about 4-5 months away). This is a meaningful milestone but not a binary approval decision. The true binary event (Phase 3 topline readout) is expected in 2H 2027, more than 12 months out. MediWound also has an approved product (NexoBrid) generating revenue, so EscharEx is not the company's only asset. Impact score of 5 reflects a mid-to-late-stage pipeline drug with a near-term milestone but no imminent binary regulatory catalyst.
The next catalyst is the interim sample-size reassessment and enrollment completion of the Phase 3 VALUE trial, expected by end of Q1 2027. A positive interim could de-risk the program and support a sample-size reduction; a negative signal would raise doubts. The topline Phase 3 readout is expected in 2H 2027, which will be the true binary event for the stock. Q3 2026 earnings on November 12, 2026 may provide an enrollment update.
Price Chart
Executive Summary
EscharEx is MediWound's late-stage pipeline drug, a bromelain-based enzymatic gel designed to debride (clean) chronic wounds like venous leg ulcers by selectively removing dead tissue. It is currently in a pivotal Phase 3 trial called VALUE (216 patients, double-blind, placebo-controlled) with co-primary endpoints of complete debridement and wound closure. Phase 2 data showed superiority over the market-leading competitor SANTYL (collagenase) in both debridement and wound closure. An independent DSMB cleared the Phase 3 trial to continue without modification in September 2026. The interim sample-size reassessment and enrollment completion are expected by end of Q1 2027, with topline Phase 3 readout anticipated in the second half of 2027. MediWound also markets the approved burn-debridement product NexoBrid, which provides current revenue. Analyst consensus is strongly bullish (11 of 12 analysts at Buy/Strong Buy) with a mean price target of $30.67, though the stock recently traded at $13.33.
How It Works
EscharEx is a gel made from bromelain (a mixture of enzymes derived from pineapple stems) that is applied directly to chronic wounds once a day. It works by selectively breaking down and removing dead or non-viable tissue (called eschar) from the wound bed, while leaving healthy tissue intact. This process, called debridement, is a critical first step in wound healing because dead tissue can harbor bacteria and block the growth of new tissue. By cleaning the wound bed, EscharEx prepares it to heal and close naturally.
Trial Status
The pivotal Phase 3 VALUE trial for venous leg ulcers is actively recruiting approximately 216 patients across 40+ sites in the US, Europe, and Israel. An independent DSMB completed a pre-specified safety review in September 2026 and recommended the trial continue without modification. Interim sample-size reassessment and enrollment completion are expected by end of Q1 2027. The company is also preparing a Phase 2/3 trial for diabetic foot ulcers and planning a study for pressure ulcers.
The Two-Sided Case
Upcoming Catalysts
- Q3 2026 earnings report on November 12, 2026 (may provide enrollment update)
- Interim sample-size reassessment and enrollment completion of Phase 3 VALUE trial by end of Q1 2027
- Phase 3 topline readout expected in 2H 2027
- Potential initiation of Phase 2/3 diabetic foot ulcer trial
Source Filing
The SecBot filing or press-release report that triggered this drug report:
MediWound Ltd. 424B5 MDWD ·Originating report